The last 10 years have witnessed radical changes in the de nition and diagnosis of the acute coronary syndrome (ACS), including myocardial infarction, as a result of the introduction of sensitive and speci c markers of myocardial damage, the cardiac troponins. One barrier to the universal acceptance of these markers has been the observation that troponin T (cTnT) concentration is commonly increased in the presence of renal failure. Initially it was believed that this constituted an important false positive limitation of the test. This was confounded by problems with the initial cTnT assay and by the observation that troponin I (cTnI) was generally not increased in these patients. However, it has recently been demonstrated that the prognostic signi cance of a raised cTnT concentration in patients with a suspected ACS is unaffected by renal impairment. Further, powerful outcome studies are now being reported demonstrating that raised concentrations of serum cTnT are predictive of mortality in haemodialysis patients. This review summarizes our current understanding of the prevalence and signi cance of raised serum cTnT concentrations in patients with kidney disease and highlights areas where our understanding is incomplete. Evidence suggests that raised troponin concentrations in uraemic patients do indeed re ect myocardial injury. In the future, patients demonstrating this abnormality may be the target for more aggressive cardiac intervention, the advantages of which have been demonstrated in the non-uraemic population.
Introduction
The cardiac troponins T (cTnT) and I (cTnI) are low molecular weight (39 000 and 26 500, respectively) protein components of the myo¢brillar contractile apparatus of heart muscle. 1, 2 Following damage to myocytes (e.g. due to myocardial infarction), cTnT and cTnI are released into the circulation. Immunoassays have been developed which are speci¢c for these proteins. Repeated studies have con¢rmed the superiority of these markers over more traditional`cardiac enzymes' (e.g. creatine kinase and its MB isoform) and troponins have gained widespread acceptance as the markers of choice in the diagnosis and risk assessment of patients with acute coronary syndrome (ACS). 3^6 In the non-dialysis population, increased troponin concentrations have been shown to be powerful prognostic markers. 7^10 Recently, the relationship between cTnT concentration and prognosis in patients with a suspected ACS has been shown to hold irrespective of level of renal function. 11
Serum troponins and renal failure
Two-year survival of patients with end-stage renal failure (ESRF) treated by dialysis is 68%. 12 The major cause of mortality in dialysis patients is cardiovascular disease. 13, 14 Left ventricular hypertrophy (LVH) or cardiac dysfunction is present in the vast majority of patients starting dialysis, predisposing them to increased risk of cardiac death. 15 Considerable resource is directed towards the primary prevention of atherosclerotic vascular disease and the identi¢cation and treatment of LVH in patients on dialysis. 16 The biochemical diagnosis of myocardial infarction in patients with renal failure has always been problematic. Commonly, increases in the cardio-speci¢c form of creatine kinase (CK-MB) were observed in the absence of myocardial infarction. 17 This was attributed to production and release of CK-MB from regenerating skeletal muscle, consequent upon the myopathy associated with chronic renal failure. 18 Early in the evaluation of troponins as markers of cardiac disease, it became apparent that serum troponin concentrations (particularly cTnT) were also commonly increased in patients with renal failure, including in the absence of an acute coronary event. 19^23 The signi¢cance of this observation has been the subject of considerable debate and remains a barrier to universal acceptance of troponins as speci¢c markers of cardiac damage. This is an important limitation given the preponderance of cardiovascular disease in patients with kidney failure.
Initially, this observation was attributed to non-speci¢c binding and re-expression of cTnT in the skeletal muscle of uraemic patients. 24 This view was reinforced by the fact that increased cTnI concentrations were less commonly observed in ESRF 23, 24 and that detection of cTnI in uraemic patients appeared to demonstrate absolute speci¢city for myocardial infarction, as de¢ned clinically. 25 As a consequence, it has been claimed that cTnI is a more useful marker of myocardial injury in patients with ESRF. 24 Later (second and third generation) modi¢cations of the assay decreased the cross-reaction with the skeletal isoform. 26 However, the observation of increased concentrations of cTnT in the serum of patients with ESRF persists, albeit at reduced frequency (see below). 23,24,26^28 Neither Haller et al. 28 nor Fredericks et al. 29 found evidence of increased skeletal muscle expression of cTnT in uraemic patients. However, this has been disputed by Ricchiuti and co-workers. 30, 31 They detected expression of predominantly lower molecular weight (34 000 -36 000) isoforms of cTnT in skeletal muscle from patients with ESRF but agree that, were these isoforms to be released from skeletal muscle into the circulation, they would not be detected by second and third generation immunoassays. Subsequently, Collinson et al. 32 demonstrated elevation of both cardiac troponins in patients with renal dysfunction, and the variable reports of cTnT vis-a© -vis cTnI have been attributed to problems with the sensitivity, diagnostic threshold and standardization of the latter assay. 32^34 This view is supported by the study of Van Lente et al. 35 These workers compared the ability of both cTnT and cTnI to predict adverse outcome in uraemic (predominantly non-dialysis) and non-uraemic patients presenting with a suspected ACS. Both troponins showed a less marked increase in serum concentration after presentation in the uraemic patients compared to the non-uraemic patients. The ability of the markers to predict subsequent ischaemic events was also reduced in the uraemic patients. However, there was no signi¢cant di¡erence in the relative abilities of the two markers in this setting.
The possibility that increased concentrations re£ect decreased clearance or analytical interference from uraemic serum does not seem to have been de¢nitively excluded, but is unlikely on the basis of pre-and postdialysis study results (see below) and that the observation is not universal amongst uraemic patients. Additionally, decreased clearance probably does not explain the di¡erences in behaviour of cTnT and cTnI given their similar molecular weights. It is increasingly accepted 28, 36, 37 that the cTnT detected in serum from patients with ESRF is derived from myocytes. This could result from subclinical myocardial ischaemic release of troponin, myocardial remodelling in the development of LVH 38, 39 or as a result of uraemic pericarditis or myocarditis. 2 It is possible that cTnT is more sensitive than cTnI in detecting such pathology. A post-mortem study appears to con¢rm both the absolute speci¢city of the later cTnT assays for myocardial damage and its increased sensitivity for myocardial pathology compared to cTnI. 40
Prevalence and clinical correlates of raised serum troponin T concentration in haemodialysis patients
Using the ¢rst generation assay, cTnT concentrations 50.1 mg/L were observed in 27/38 haemodialysis patients. 22 Subsequently, the reported frequency of raised troponin concentrations in the dialysis population has varied depending on the assay used, whether cTnTor cTnI have been studied and the cut-o¡ chosen. Additionally, each manufacturer's cTnI assay uses a di¡erent antibody, whereas a single manufacturer only (Roche Diagnostics Ltd, Lewes, UK) markets the cTnT assay. Given this, and the confusion that has surrounded some of the earlier studies, the following comments are predominantly restricted to studies using second and third generation cTnT assays. The data are summarized in Table 1 .
Generally, the prevalence appears to be somewhat lower than that originally observed. McLaurin et al. 24 observed cTnT concentrations 40.2 mg/ L in 3/18 haemodialysis patients using a second generation assay, compared to17/24 using a ¢rst generation assay. Baum et al. 27 observed cTnT concentrations 40.2 m>g/ L in 11/30 haemodialysis patients using the ¢rst generation assay compared to 6/30 with the second generation assay. Similarly, Haller et al. 28 observed concentrations 50.2 mg/ L in 38 and 23 of 97 haemodialysis patients using ¢rst and second generation assays, respectively. The prevalence of increased cTnT concentration correlated with cardiac risk in their patients.
Ooi and House 36 observed increased cTnT concentrations (40.1 mg/L) in 429% of 174 haemodialysis patients without overt acute coronary disease; only 11% had concentrations 50.01 mg/L (i.e. as typically observed in a non-uraemic population). Mean concentrations were higher in older patients and in patients with known ischaemic heart disease (IHD) and/or diabetes mellitus, but were unrelated to dialysis adequacy. Reports by other authors using the second generation assay are broadly consistent (see Table 1 ). 37,38,41^44 Wayand et al. 45 observed cTnT concentrations 40.1 mg/L in 12/59 haemodialysis patients; the prevalence of high cTnT concentration did not di¡er signi¢cantly between patients with and without cardiac symptoms or disease, although the subgroups were relatively small. Roppollo et al. 46 observed cTnT concentrations 40.1 mg/L in 25/49 haemodialysis patients; only 3/83 had elevated cTnI concentrations. Patients with diabetes were more likely to have elevated cTnT concentrations. Lowbeer Relative risk of death strongly associated with baseline cTnT concentration (3 years) First generation assay: 7 enzyme-linked immunosorbent assay on ES TM system (CardiAC Troponin T; Boehringer Mannheim, Indianapolis IN, USA). Second generation assay: 26, 27 Enymun on an ES system (Boehringer Mannheim) or electrochemiluminescence immunoassay (ECLIA) on an Elecsys TM system (Roche Diagnostics, Lewes, UK). Third generation assay: 1 ECLIA on an Elecsys system (Roche Diagnostics) following restandardization. et al. 38 observed increased (50.1 mg/L) cTnT (but not cTnI) concentrations in 20/36 haemodialysis patients. Mean cTnT concentration was higher in patients with known IHD and higher in patients with diabetes mellitus irrespective of IHD. Increases were more commonly observed amongst patients with LVH or heart valve disease and there was a signi¢cant correlation between left ventricular mass index (LVMI) and cTnT. Mallamaci et al. 47 also observed a signi¢cant relationship between cTnT concentration and LVMI in 199 haemodialysis patients, only 12 of whom had undetectable (50.01 mg/L) cTnT concentrations. Furthermore, they suggested that cTnT could be used as a simple`bedside' screening test for LVH in haemodialysis patients. 48 In the largest studies to date, Apple et al. 49 observed cTnT concentrations 50.1 mg/L in 20% of 733 haemodialysis patients. By contrast, cTnI was only increased (50.6 mg/L) in 0.4% of their patients. Iliou et al. 50 observed cTnT concentrations 40.1 mg/L in 19% of 258 haemodialysis patients; only 2% demonstrated elevated concentrations of cTnI. Left ventricular mass was associated with cTnT, but not cTnI, concentration, and it has been suggested 49 that LVH may explain the di¡ering behaviour of these markers in haemodialysis patients, with a di¡erent release pattern of cTnT compared to cTnI. Interestingly, however, cTnT concentrations were not increased in a small cohort of post-renal transplant patients, despite the presence of LVH. 51
How are serum troponin T concentrations related to outcome amongst haemodialysis patients?
Irrespective of the actual prevalence of increased troponin concentration in the serum of haemodialysis patients, the most striking observation is the relationship with outcome. In the ¢rst study to address this, Apple et al. 23 observed raised cTnT concentrations (40.2 mg/L) in 12/16 haemodialysis patients with type 1 diabetes. After 1 year, four of these 12 patients had su¡ered a fatal myocardial infarction. More recent, larger studies provide further evidence that raised troponin concentrations are powerful predictors of mortality in the haemodialysis population (see Table 1 ).
Wayand et al. 45 Some studies have not observed an association between cTnT and mortality. 37, 43 However, these studies were smaller (nˆ20 and nˆ81, respectively) and had shorter follow-up periods.
How variable are serum troponin T concentrations in dialysis patients? Does dialysis affect serum troponin T concentration?
Few studies cite data addressing intra-individual variability of serum troponin concentration in uraemia. In the short-term (560 h), Ooi and House 36 found serum cTnT concentrations to be relatively stable in haemodialysis patients. However, over a longer time-span (435 days), 44/125 patients demonstrated 450% variability and 18 showed more than doubling in concentration. Similarly, Wayand et al. 45 clearly demonstrated that, in the absence of an acute coronary event, patients may have cTnT concentrations both below and above the diagnostic threshold (0.1 mg/L) on di¡erent occasions. Both studies observed a slight increase in serum cTnT concentration post-dialysis, which they attributed to haemoconcentration. Conversely, Lowbeer et al. 38 and Frankel et al. 22 found no di¡erence between pre-and post-dialysis concentrations of cTnT.
What is the evidence-base amongst peritoneal dialysis patients?
There have been relatively few studies of serum troponin in peritoneal dialysis (PD) patients. A ¢rst generation assay demonstrated elevated cTnT concentration in 12/21 PD patients. 22 Using a second generation assay, Lowbeer et al. 38 observed elevated (50.1 mg/L) cTnT (but not cTnI) concentrations in eight of 26 PD patients in the absence of acute myocardial infarction. Concentrations were higher in the ¢ve patients known to have ischaemic heart disease and, in the group as a whole, there was a weak negative association with serum creatinine concentration. Four-year follow-up of these patients, during which 15 patients died, demonstrated that an initial cTnT concentration 50.04 mg/L was a strong predictor of all-cause mortality. 54 Although fascinating, the study was fairly small and the conclusions were based upon troponin measurements in a single serum sample taken from a randomly selected group of PD patients. There is a need for further research in this area, especially given that LVH is more common amongst long-term PD patients compared to haemodialysis patients. 55
Troponin T in patients with chronic kidney disease who are not on dialysis
Cardiac disease develops early in the progression of chronic kidney disease (CKD). Clinical manifestations and echocardiographic evidence of cardiovascular disease are already present in a high proportion of patients starting renal replacement therapy and are independent mortality risk factors. About 80% of patients commence dialysis with LVH, left ventricular dilatation or systolic dysfunction. These are predictive of later development of IHD, heart failure and increased mortality. Although tests to assess cardiac function and diagnose IHD in asymptomatic patients are available (in the form of cardiac echocardiography, myoview scans and exercise electrocardiograms), for health economic reasons they are not o¡ered to all CKD patients. The ability to detect cardiac disease at an early stage would facilitate aggressive and focused treatment of those at increased risk. Although traditional risk factors for cardiac disease such as diabetes mellitus, hypertension, smoking, family history, age and race play a signi¢cant part, cardiac mortality remains markedly higher even in their absence, and associations between many classical risk factors and cardiac outcomes in ESRF are inconsistent. Many of these traditional cardiac risk factors, as well as those speci¢cally or more commonly associated with renal disease (i.e. anaemia, hyperparathyroidism and LVH), can be modi¢ed by aggressive therapy. This does, however, require early identi¢cation of patients at increased risk of cardiac disease. 56 It is possible that cTnT could be used to screen for cardiovascular risk in pre-ESRF CKD patients.
Currently, there is a paucity of data regarding cTnT in pre-ESRF CKD patients. cTnT was undetectable in nine CKD patients with glomerular ¢ltration rates (GFR) of 40 -60 mL/min (serum creatinine 120 -200 mmol/L). 32 However, it exceeded 0.1 mg/ L in four of 46 CKD patients with GFR 540 mL/min (serum creatinine 4200 mmol/ L) who were not receiving dialysis, and was between 0.01 and 0.1 mg/L in a further 22. The authors did not report the clinical correlates such as LVH and mortality in the two groups. 32 Mockel et al. 37 also observed cTnT concentrations 40.1 mg/L in 4/20 pre-ESRF patients without clinical evidence of an ACS. Roppollo et al. 46 observed increased cTnT concentrations in only 1/83 CKD patients not undergoing dialysis (mean serum creatinine in their cohort was 238 mmol/L).
How should acute coronary syndrome be diagnosed in the context of renal impairment?
In recent years myocardial infarction has been included in the wider acute coronary syndrome, which also includes states of lesser ischaemic injury (i.e. patients with severe stable or unstable angina pectoris positive for cardiac troponin). 4 The use of cardiac troponins to diagnose ACS has revolutionized patient management. Unfortunately, it has failed to simplify the diagnosis of ACS in patients with ESRF. In non-uraemic patients an increased serum cTnT concentration in the presence of ischaemic symptoms and/or characteristic ECG changes is generally considered su¤cient evidence to satisfy the diagnosis. In the setting of ESRF, this is clearly not the case and there is considerable clinical confusion as to how the diagnosis can be established in such patients.
Diagnosis of ACS in ESRF is complicated by the fact that such patients are at higher risk of silent myocardial ischaemia and atypical clinical presentations. 57 In addition, a previous history of angina is often absent. ECG investigations are also di¤cult to interpret; ECG abnormalities such as left bundle branch block and left ventricular strain patterns are extremely common, making evaluation di¤cult. 58 Consequently, ACS may be missed or there may be a signi¢cant delay in diagnosis. This, coupled with an apparent reluctance to use aspirin, b-blockers, thrombolytic therapy or refer for angiography or angioplasty patients with moderate renal insu¤ciency may partly explain the signi¢cantly higher mortality seen in this group. In a recent study, 1-year mortality post myocardial infarction was 24% in patients with normal renal function compared to 66% in patients with moderate renal insu¤ciency (serum creatinine 220 -345 mmol/L). 59 The discovery that cardiac troponins are commonly but not universally increased in patients on dialysis creates a diagnostic dilemma. Several strategies have been proposed, all of which have major disadvantages. It has been suggested that a higher threshold of cTnT (0.5 mg/L) could be used to make a diagnosis in such patients. 35 However, this would result in coronary events in those with previously normal levels of cTnT being missed. Alternatively, the apparent high speci¢city of cTnI for clinically diagnosed myocardial infarction in uraemic patients could be useful, 24, 25 although its sensitivity has not been studied in a large cohort. Indeed, such studies are di¤cult to undertake since an increase in troponin concentration is one of the de¢ning criteria for the ACS. 4 Possibly a di¡erential use of cTnT and cTnI may be used, 46, 60 or it may be appropriate to look for evolutional change in serum cTnT concentration; as stated above, in the short term, serum cTnT concentrations are relatively stable within individual patients 36 and increase following myocardial infarction. 35 The major disadvantage of this approach is that it inevitably leads to a delay in intervention. 61 Recently published data from the GUSTO IV study suggest that cTnTconcentrations in patients presenting with suspected ACS are predictive of short-term outcomes regardless of the level of creatinine clearance. 11 An abnormal cTnTconcentrationat baseline was associated with an increased risk of death within 30 days in all patients (adjusted odds ratio 3.4). Although this study included very few patients on dialysis, the ¢ndings suggest there may well be a strong case for aggressive management and investigation of any patient presenting with chest pain and a raised cTnT concentration regardless of their level of renal function.
Currently, there does not seem to be a straightforward answer to the question posed above. A great deal more work is needed to determine the usefulness of cTnT as a clinical tool in patients with suspected ACS and renal failure. Whilst a negative cTnT concentration is clearly useful in this setting, management problems arise in ESRF patients with a suspected ACS who have an increased cTnT concentration. In the absence of a simple gold standard diagnostic test for ACS, clinical and cardiovascular-speci¢c outcomes studies in this population will hopefully provide the evidence base for the development of useful management guidelines.
Summary
Serum troponin (predominantly cTnT) concentrations are commonly increased in patients with ESRFand it is likely that this is attributable to release from myocytes, possibly due to LVH. In haemodialysis patients at least, there is wide within-individual biological variability. There are strong data linking increased serum cTnT concentrations to poor long-term outcome in haemodialysis patients. cTnT concentration may be a useful tool in risk strati¢cation of haemodialysis patients and in selection of patients who would bene¢t from more invasive cardiac investigation and treatment. To date, no studies have addressed this possibility.
In patients receiving PD, the biological variability and the acute e¡ects of dialysis on serum cTnT concentration have not been studied. There are limited data suggesting that increased troponin concentrations are more commonly observed in PD patients with IHD and that this may predict poor outcome. There have been no large-scale prospective studies of the prognostic signi¢cance of a raised cTnT concentration at entry to a PD programme, or of the relationship between cTnT and LVH in PD patients.
There are very limited data addressing the prevalence of raised cTnT in CKD patients who are not receiving dialysis. With increasing emphasis on the prevention and management of cardiovascular disease in CKD patients who have not reached ESRF, 62, 63 there is an urgent need for studies addressing the gaps in our understanding in such patients. Speci¢cally, it is not known: (1) at what stage in renal dysfunction the increase in cTnT occurs; (2) whether cTnT concentrations continue to rise as kidney disease progresses; and (3) whether there is a correlation between cardiac dysfunction and cTnT in the pre-ESRF patients. Iden-ti¢cation of the point at which this increase occurs, and in which patients, could provide important information about the development of cardiovascular disease in patients with CKD, be useful for risk strati-¢cation and would provide useful guidance in the diagnosis or exclusion of ACS in pre-ESRF patients.
The powerful outcomes data that are emerging from studies of haemodialysis patients has moved our understanding beyond the point where raised troponin concentrations in renal failure can be considered false positives. Future studies will need to address the gaps in our understanding in PD and pre-ESRF patients. Perhaps more excitingly, increased troponin concentrations may be used to identify patients who will bene¢t from more aggressive cardiac intervention, as has been observed in non-uraemic populations. 64
Note added in proof
Two further relevant articles have been published as our review was going to press. In keeping with other studies, deFilippi et al. (JAMA 2003 ; 290: 353-9) have demonstrated a continuous relationship between increasing cTnT concentration and all cause mortality in 224 haemodialysis patients over a mean follow-up period exceeding 2 years. Further, amongst a subset of their patients who underwent coronary angiography, a relationship was observed between cTnT concentration and the extent of coronary artery disease: no relationship was found with LVH. This may point towards silent ischaemic events rather than LVH as the cause of increased cTnT in patients with kidney disease. Wood et al. (Nephrology, Dialysis and Transplantation 2003; 18: 1610 -15) have also rea¤rmed the prognostic signi¢cance of an increased baseline cTnT concentration for predicting a subsequent cardiovascular event. A cohort of ESRF patients being prepared for, but not having commenced, renal replacement therapy was followed over a period of 2 years. This study con¢rms that it is kidney disease rather than dialysis that causes cTnT to increase, but it is relatively uninformative as to the pathology underlying this event. As the authors discuss, a representative stratum of patients with varying degrees of kidney disease was not studied (all patients had serum creatinine concentrations 4500 mmol/L and the mean concentration was 1037 mmol/L) and no attempt was made to evaluate cardiac function.
